Media headlines about Heron Therapeutics (NASDAQ:HRTX) have been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Heron Therapeutics earned a news impact score of 0.01 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 96 out of 100, meaning that recent news coverage is extremely likely to have an impact on the company’s share price in the near future.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Heron Therapeutics, Inc. (HRTX) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com)
- Short Interest in Heron Therapeutics, Inc. (NASDAQ:HRTX) Decreases By 9.8% (americanbankingnews.com)
- Heron Therapeutics Inc (HRTX) Triple EMA Picking up Steam – Evergreen Caller (evergreencaller.com)
- Why Is Heron Therapeutics, Inc. (HRTX) Moving So Hard, So Fast? – StockNewsMagazine (stocknewsmagazine.com)
- Heron Therapeutics, Inc. (HRTX) has a value of $16.90 per share While Progenics Pharmaceuticals, Inc. (PGNX) is … – Stocks Gallery (stocksgallery.com)
Several equities research analysts have commented on HRTX shares. Cantor Fitzgerald restated an “overweight” rating on shares of Heron Therapeutics in a research report on Monday, June 26th. Zacks Investment Research upgraded Heron Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research report on Wednesday, July 12th. Cowen and Company restated a “buy” rating and issued a $40.00 price objective on shares of Heron Therapeutics in a research report on Friday, May 26th. ValuEngine upgraded Heron Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Finally, Aegis restated a “buy” rating and issued a $33.00 price objective on shares of Heron Therapeutics in a research report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating and eleven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $31.00.
Shares of Heron Therapeutics (NASDAQ:HRTX) traded up 0.30% on Friday, hitting $16.45. The stock had a trading volume of 502,381 shares. Heron Therapeutics has a 12 month low of $12.21 and a 12 month high of $24.00. The firm has a 50 day moving average of $14.92 and a 200 day moving average of $14.38.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($1.00) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.94) by $0.06. The company had revenue of $3.63 million during the quarter, compared to analysts’ expectations of $1.96 million. Equities analysts expect that Heron Therapeutics will post ($3.72) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Heron Therapeutics (NASDAQ:HRTX) Getting Somewhat Favorable News Coverage, Analysis Finds” was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/07/30/heron-therapeutics-nasdaqhrtx-earning-somewhat-favorable-press-coverage-study-shows-updated-updated-updated.html.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.